APA (7th ed.) Citation

Bishnoi, S., Kotasek, D., Aghmesheh, M., Yau, T., Cosman, R., Prawira, A., . . . Tse, A. N. (2024). Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study. Cancer (0008543X), 130(11), 1991. https://doi.org/10.1002/cncr.35226

Chicago Style (17th ed.) Citation

Bishnoi, Sarwan, et al. "Dual CTLA‐4 and PD‐1 Checkpoint Blockade Using CS1002 and CS1003 (nofazinlimab) in Patients with Advanced Solid Tumors: A First‐in‐human, Dose‐escalation, and Dose‐expansion Study." Cancer (0008543X) 130, no. 11 (2024): 1991. https://doi.org/10.1002/cncr.35226.

MLA (9th ed.) Citation

Bishnoi, Sarwan, et al. "Dual CTLA‐4 and PD‐1 Checkpoint Blockade Using CS1002 and CS1003 (nofazinlimab) in Patients with Advanced Solid Tumors: A First‐in‐human, Dose‐escalation, and Dose‐expansion Study." Cancer (0008543X), vol. 130, no. 11, 2024, p. 1991, https://doi.org/10.1002/cncr.35226.